Nanexa enters EUR 1.165 billion global licensing deal with Novo Nordisk for long-acting injectables
Bitget2026/09/24 16:26- Nanexa entered a global exclusive license and collaboration agreement with Novo Nordisk for its PharmaShell drug-delivery platform.
- Deal targets long-acting injectable peptide drugs for obesity, type 2 diabetes, and other cardiometabolic indications.
- Novo secured rights for up to five development programs, aiming for monthly and quarterly dosing profiles.
- Nanexa is eligible for up to EUR 1.165 billion, including EUR 615 million in upfront and development and regulatory milestones.
- Agreement also includes sales milestones and low single-digit royalties on future product sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold Fields said to weigh sweetening Northern Star bid with cash
Under continuous pressure from inflation and interest rate hike concerns, US Treasury sell-off intensifies; 30-year yield once surpassed 5.6%, hitting a more than 24-year high
U.S. long-term Treasury yields continued to rise on Tuesday, extending the recent sharp upward trend.
The US releases the final batch of strategic oil reserves, up to 40 million barrels, urging Europe to follow suit.
This is the final batch of the 172 million barrels of reserves released by the United States in this round; after this release, the U.S. Strategic Petroleum Reserve will drop to its lowest level since 1982, approaching legal and operational red lines. Meanwhile, the U.S. Secretary of Energy criticized some European countries for releasing far less than expected, urging them to fulfill their commitments. Currently, gasoline and diesel prices in the U.S. remain high, and less than two months remain until the midterm elections. On Tuesday, WTI crude oil futures fell by 3.95%.
Raphael Zagury: Bitcoin will eventually surpass gold
Crypto prices
More
